Cetuximab in metastatic squamous cell cancer of the skin: A Swiss case series by Conen, Katrin L et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Cetuximab in metastatic squamous cell cancer of the skin: A Swiss case
series
Conen, Katrin L; Fischer, Natalie; Hofbauer, Günther F L; Shafaeddin-Schreve, Bahar; Winterhalder,
Ralph; Rochlitz, Christoph; Zippelius, Alfred
Abstract: Background: There is current evidence that non-melanoma skin cancers can be successfully
treated with cetuximab. Objective: To evaluate the use and efficacy of cetuximab (with or without
radiotherapy) in a series of previously treated patients with metastatic squamous cell cancer of the skin
(SCCS) in Switzerland. Methods: We performed a retrospective analysis of six patients from four centers.
Endpoints were disease control rates (DCRs) at 4-8 weeks, 12-14 weeks and 20-36 weeks of treatment.
Treatment-related toxicity was evaluated additionally. Results: A median of 14 cycles of cetuximab were
applied. DCR was 67% at 4-8 weeks, 50% at 12-14 weeks and 33% at 20-36 weeks. In 4-8 weeks responders,
mean relapse-free time was 12 ± 6.2 months and mean overall survival was 25 ± 16.2 months. Grade
I-III acne-like rash developed around week 3 of treatment in 83%. Conclusions: Cetuximab treatment in
patients with metastatic SCCS achieved an overall DCR of 67% at 4-8 weeks of treatment. This study
underlines the current evidence that SCCS can be successfully treated with cetuximab. Introduction
In Switzerland, squamous cell cancer of the skin (SCCS) and basal cell cancer are the most common
cutaneous cancers with no less than 15,000 estimated new cases diagnosed per year [1]. The median
age at diagnosis of SCCS is 70 years [2]. Most patients with primary SCCS have an excellent prognosis
due to the possibility of local treatment leading to long-term disease control. High-risk groups for SCCS
such as organ transplant recipients or chronic lymphatic leukemia patients are vitally threatened [3,4]. In
patients with metastatic disease, long-term overall survival rates are <20% for patients with local lymph
node metastases and <10% for patients with distant metastases (mainly involving the lungs, brain, liver,
skin and bones) [2]. The treatment of advanced-stage SCCS is challenging as surgical excision becomes
impossible. Few therapeutic options are available and the evidence supporting their use is based mainly
on non-randomized trials [5,6]. Cisplatin-based chemotherapeutic regiments have short-term efficacies
with an overall response rate of up to 80% in locally advanced SCCS [5,6]. However, the severe toxic side
effects associated with these regimens limit their use in elderly patients, who make up the majority of
cases of SCCS. Alternative treatment options are clearly needed. The epidermal growth factor receptor
(EGFR) is a membrane-bound tyrosine kinase receptor that is highly expressed in normal epidermal
keratinocytes, many epithelial tumors and in particular SCCS [7,8]. EGFR expression in SCCS shows no
mutations or loss of expression as in other tumors [8]. EGFR is activated by ligand binding and receptor
dimerization which subsequently activates multiple downstream pathways involved in cell proliferation
and survival [7]. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for the
treatment of squamous cell cancer of the head and neck and colorectal cancer. In a published phase II
trial, single-agent cetuximab demonstrated promising clinical activity in treatment-naïve patients with
unresectable, locally advanced SCCS, achieving an overall disease control rate (DCR) of 69% and a
response rate of 28% [9]. Several retrospective single case reports and case series have described the
effects of cetuximab in both treatment-naïve and multiply pretreated patients with metastatic SCCS
[10,11,12,13,14,15]. A recently published summary of 54 cases of locally advanced and metastatic SCCS
treated with cetuximab reported a 30% partial response and a 18.5% complete response in these patients
[15]. Overall, pretreated patients seemed to benefit less than previously untreated patients. Since the
clinical efficacy of cetuximab in colorectal tumors and squamous cell cancer of the head and neck has
been correlated with early development of acne-like skin rash, the predictive role of skin rash in patients
with SCCS treated with cetuximab deserves further study [9,15]. The main objective of this study
was to review the use, efficacy and toxicity of cetuximab in a series of previously treated patients with
metastatic SCCS in Switzerland in the context of the published literature. Methods Patient records
from four participating centers in Switzerland were retrospectively reviewed to identify individuals who
presented with disease progression after any previous therapy of metastatic SCCS and who were treated
with cetuximab between 2010 and 2012. We collected baseline data from the patients’ records using a
standardized questionnaire as described below. The primary study endpoint was the DCR at 4-8 weeks,
12-14 weeks and 20-36 weeks of treatment. Moreover, relapse-free time under cetuximab treatment, i.e.
the time between cetuximab treatment start and disease progression, as well as overall survival at the time
of final data analysis was evaluated. We also examined treatment-related side effects and their correlation
with disease control. As all data were collected as part of routine diagnosis and treatment, no ethical
approval was required. Questionnaire To guide collection of baseline data from records by the physicians,
a questionnaire including demographic data as well as personal and medical factors was used. Other
characteristics recorded included the date of first disease presentation, pathological status, interventions,
medications, control rates, dose and duration of cetuximab, adverse events that were judged to have
been caused by cetuximab and overall health status (Eastern Cooperative Oncology Group [ECOG]
performance status). Cetuximab-related adverse events were classified according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events (version 3.0). Tumor response (complete
response, partial response) was assessed every 2-3 month until disease progression according to RECIST
(version 1.1.) criteria in computed tomography or magnetic resonance imaging [16]. Statistics Statistical
analysis was performed using the Excel software program (version 2010). Analyses were performed for
the entire patient cohort and percentages and descriptive statistics were used to summarize the data.
Results Baseline Characteristics Six patients with previously treated metastatic SCCS were identified
who received cetuximab between 2010 and 2012. As listed in table 1, the median age of the patient
population was 77 ± 21.8 years. There was a male predominance (67 vs. 33%). Overall, patients received
a median of 14 ± 12 cycles of cetuximab (range 3-21). All six patients received a cetuximab loading dose
of 400 mg/m2 followed by a weekly dose of 250 mg/m2. After 2-4 weeks, treatment was changed to a
two-weekly application of 500 mg/m2 in three of the six patients. The primary tumor was located in
the area of the head in four (67%) patients and in the trunk and extremities on one (17%) patient each.
All patients suffered from visceral metastases commonly involving the lungs, liver or brain. All patients
had previously undergone surgical resection and had been previously treated either with chemotherapy
(cisplatin, 5-fluorouracil) or radiotherapy. Two of the six (33%) patients received cetuximab treatment
concomitant to radiotherapy. The ECOG performance status of patients at baseline was 0 in two (33%)
patients and 1 in four (67%) patients.
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 Introduction 
 In Switzerland, squamous cell cancer of the skin 
(SCCS) and basal cell cancer are the most common cuta-
neous cancers with no less than 15,000 estimated new cas-
es diagnosed per year  [1] . The median age at diagnosis of 
SCCS is 70 years  [2] . Most patients with primary SCCS 
have an excellent prognosis due to the possibility of local 
treatment leading to long-term disease control. High-risk 
groups for SCCS such as organ transplant recipients or 
chronic lymphatic leukemia patients are vitally threat-
ened  [3, 4] . In patients with metastatic disease, long-term 
overall survival rates are <20% for patients with local 
lymph node metastases and <10% for patients with dis-
tant metastases (mainly involving the lungs, brain, liver, 
skin and bones)  [2] .
 The treatment of advanced-stage SCCS is challenging 
as surgical excision becomes impossible. Few therapeutic 
options are available and the evidence supporting their 
use is based mainly on non-randomized trials  [5, 6] . Cis-
platin-based chemotherapeutic regiments have short-
term efficacies with an overall response rate of up to 80% 
in locally advanced SCCS  [5, 6] . However, the severe tox-
ic side effects associated with these regimens limit their 
use in elderly patients, who make up the majority of cases 
of SCCS. Alternative treatment options are clearly needed.
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 Abstract 
 Background: There is current evidence that non-melanoma 
skin cancers can be successfully treated with cetuximab.  Ob-
jective: To evaluate the use and efficacy of cetuximab (with 
or without radiotherapy) in a series of previously treated
patients with metastatic squamous cell cancer of the skin 
(SCCS) in Switzerland.  Methods: We performed a retrospec-
tive analysis of six patients from four centers. Endpoints were 
disease control rates (DCRs) at 4–8 weeks, 12–14 weeks and 
20–36 weeks of treatment. Treatment-related toxicity was 
evaluated additionally.  Results: A median of 14 cycles of ce-
tuximab were applied. DCR was 67% at 4–8 weeks, 50% at 
12–14 weeks and 33% at 20–36 weeks. In 4–8 weeks re-
sponders, mean relapse-free time was 12 ± 6.2 months and 
mean overall survival was 25 ± 16.2 months. Grade I–III acne-
like rash developed around week 3 of treatment in 83%.  Con-
clusions: Cetuximab treatment in patients with metastatic 
SCCS achieved an overall DCR of 67% at 4–8 weeks of treat-
ment. This study underlines the current evidence that SCCS 
can be successfully treated with cetuximab. 
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 The epidermal growth factor receptor (EGFR) is a 
membrane-bound tyrosine kinase receptor that is highly 
expressed in normal epidermal keratinocytes, many epi-
thelial tumors and in particular SCCS  [7, 8] . EGFR ex-
pression in SCCS shows no mutations or loss of expres-
sion as in other tumors  [8] . EGFR is activated by ligand 
binding and receptor dimerization which subsequently 
activates multiple downstream pathways involved in cell 
proliferation and survival  [7] . Cetuximab is an anti-EGFR 
monoclonal antibody that has been approved for the 
treatment of squamous cell cancer of the head and neck 
and colorectal cancer. In a published phase II trial, single-
agent cetuximab demonstrated promising clinical activ-
ity in treatment-naïve patients with unresectable, locally 
advanced SCCS, achieving an overall disease control rate 
(DCR) of 69% and a response rate of 28%  [9] . Several ret-
rospective single case reports and case series have de-
scribed the effects of cetuximab in both treatment-naïve 
and multiply pretreated patients with metastatic SCCS 
 [10–15] . A recently published summary of 54 cases of lo-
cally advanced and metastatic SCCS treated with cetux-
imab reported a 30% partial response and a 18.5% com-
plete response in these patients  [15] . Overall, pretreated 
patients seemed to benefit less than previously untreat-
ed patients. Since the clinical efficacy of cetuximab in 
colorectal tumors and squamous cell cancer of the head 
and neck has been correlated with early development of 
acne-like skin rash, the predictive role of skin rash in pa-
tients with SCCS treated with cetuximab deserves further 
study  [9, 15] .
 The main objective of this study was to review the use, 
efficacy and toxicity of cetuximab in a series of previous-
ly treated patients with metastatic SCCS in Switzerland in 
the context of the published literature.
 Methods 
 Patient records from four participating centers in Switzerland 
were retrospectively reviewed to identify individuals who present-
ed with disease progression after any previous therapy of meta-
static SCCS and who were treated with cetuximab between 2010 
and 2012. We collected baseline data from the patients’ records 
using a standardized questionnaire as described below. The pri-
mary study endpoint was the DCR at 4–8 weeks, 12–14 weeks and 
20–36 weeks of treatment. Moreover, relapse-free time under ce-
tuximab treatment, i.e. the time between cetuximab treatment start 
and disease progression, as well as overall survival at the time of 
final data analysis was evaluated. We also examined treatment-
related side effects and their correlation with disease control. As all 
data were collected as part of routine diagnosis and treatment, no 
ethical approval was required.
 Questionnaire 
 To guide collection of baseline data from records by the physi-
cians, a questionnaire including demographic data as well as per-
sonal and medical factors was used. Other characteristics recorded 
included the date of first disease presentation, pathological status, 
interventions, medications, control rates, dose and duration of ce-
tuximab, adverse events that were judged to have been caused by 
cetuximab and overall health status (Eastern Cooperative Oncol-
ogy Group [ECOG] performance status). Cetuximab-related ad-
verse events were classified according to the National Cancer In-
stitute’s Common Terminology Criteria for Adverse Events (ver-
sion 3.0). Tumor response (complete response, partial response) 
was assessed every 2–3 month until disease progression according 
to RECIST (version 1.1.) criteria in computed tomography or mag-
netic resonance imaging  [16] .
 Statistics 
 Statistical analysis was performed using the Excel software pro-
gram (version 2010). Analyses were performed for the entire pa-
tient cohort and percentages and descriptive statistics were used to 
summarize the data.
 Results 
 Baseline Characteristics 
 Six patients with previously treated metastatic SCCS 
were identified who received cetuximab between 2010 
and 2012. As listed in  table 1 , the median age of the pa-
tient population was 77 ± 21.8 years. There was a male 
predominance (67 vs. 33%). Overall, patients received a 
median of 14 ± 12 cycles of cetuximab (range 3–21). All 
six patients received a cetuximab loading dose of 400 mg/
m 2 followed by a weekly dose of 250 mg/m 2 . After 2–4 
weeks, treatment was changed to a two-weekly applica-
tion of 500 mg/m 2 in three of the six patients. The pri-
mary tumor was located in the area of the head in four 
(67%) patients and in the trunk and extremities on one 
(17%) patient each. All patients suffered from visceral 
metastases commonly involving the lungs, liver or brain. 
All patients had previously undergone surgical resection 
and had been previously treated either with chemothera-
py (cisplatin, 5-fluorouracil) or radiotherapy. Two of the 
six (33%) patients received cetuximab treatment con-
comitant to radiotherapy. The ECOG performance status 
of patients at baseline was 0 in two (33%) patients and 1 
in four (67%) patients.
 Response and DCRs 
 At week 4–8, the overall DCR was 67% (four of six pa-
tients). One patient (17%) treated with radiotherapy and 
cetuximab showed complete response, three (50%) pa-
tients achieved partial response, and disease progression 
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was recorded in the remaining two patients ( table 2 ). The 
DCR was 50% (three patients) at weeks 12–14 and 33% 
(two patients) at weeks 20–36. The patient achieving 
complete response after 4 weeks of treatment remained a 
complete responder by the end of the study. Additionally, 
one patient who achieved partial remission by the first as-
sessment at week 4–8 maintained it by the last assessment 
status at weeks 20–36. Therefore, two of the six treated 
patients (33%) were still receiving cetuximab and show-
ing disease control at the time of study evaluation ( ta-
ble 2 ).
 Relapse-Free Time and Overall Survival 
 Mean relapse-free time in the total study patients was 
6 ± 7.2 month. In the four cetuximab responders at 4–8 
weeks, mean relapse-free time was 12 ± 6.2 month ( ta-
ble 3 ). At the time of final study analysis, total overall sur-
vival was 12 ± 14.9 month, while two patients were still 
alive. In the responders-only patient group after 4–8 weeks 
of treatment with cetuximab, mean overall survival at the 
time of final analysis was 25 ± 16.2 month ( table 3 ).
 Table 1.  Baseline characteristics of the six patients with metastatic 
SCCS
Mean ± SD 
Age 77 ± 21.8
Cetuximab doses 14 ± 12
n %
Sex
Female
Male
2
4
33
67
Primary SCCS location
Head
Trunk
Extremity
4
1
1
67
17
17
Visceral metastases 
(lung, liver, brain)
6 100
Previous surgery 6 100
Previous chemotherapy
(cisplatin and 5-fluorouracil)
2 33
Previous radiotherapy 4 67
Cetuximab 6 100
Concomitant cetuximab and
radiotherapy
2 33
ECOG PS at cetuximab start
0 
1
2
4
33
67
PS = Performance status.
 Table 2.  Response and DCRs
Variable  Response at weeks
 4 – 8 12 – 14 20 – 36
Complete response 1 (17%) 1 (17%) 1 (17%)
Partial response 3 (50%) 1 (17%) 1 (17%)
Stable disease 0 (0%) 1 (17%) 0 (0%)
Progressive disease 2 (33%) 1 (17%) 1 (17%)
DCR 67 51 33
 Table 3. Relapse-free time and overall survival (mean ± SD)
Variable Months
Mean relapse-free time
Total (n = 6) 6 ± 7.2
Responders at 4 – 8 weeks (n = 4) 12 ± 6.2
Overall survival at time of final analysis
Total (n = 6; 2 still alive) 12 ± 14.9
Excluding patients alive (n = 4) 10 ± 8.9
Responders at 4 – 8 weeks (n = 4; 2 still alive) 25 ± 16.2
 Table 4.  Treatment-related adverse events
Adverse event category All grades  Grades 3 and 4
n %  n %
Any 6 100 3 50
Acne-like rash 5 83 3 50
Xerosis 2 33 0 0
Paronychia 1 17 0 0
Infection 1 17 0 0
Eye disorder1 2 33 0 0
 1 Eye disorder includes conjunctivitis, eye dryness and blepha-
ritis.
 Table 5.  Correlation of acne-like rash and response rate at 4 – 8 
weeks
Variable Response  Rash
n %  n %
Complete response 1 17 1 100
Partial response 3 50 3 100
Stable disease 0 0 0 0
Progressive disease 2 33 1 50
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 Treatment-Related Side Effects and Association of 
Acne-Like Rash with Disease Control 
 The adverse reactions observed during therapy are 
outlined in  table 4 . Treatment-related side effects, mainly 
affecting the skin, were observed in all six patients. One 
85-ear-old patient developed a serious adverse event as a 
severe infection leading to death. Grade I–III acne-like 
rash developed in five (83%) patients around week 3 of 
treatment ( table 4 ). All four patients who had their dis-
ease controlled at 4–8 weeks showed an acne-like rash, 
and one patient had a rash without disease control ( ta-
ble 5 ).
 Discussion 
 When metastatic SCCS requires systemic palliation, 
treatment with conventional chemotherapy, such as cis-
platin, is often precluded by patient age or medical co-
morbidities  [17] . This study underlines the evidence that 
non-melanoma skin cancers can be successfully treated 
with cetuximab. Disease control was observed in four 
(67%) of our patients by treatment week 4–8 with a mean 
relapse-free time of 6–12 months in these patients. A 
phase II trial of 36 treatment-naïve patients with unre-
sectable SCCS documented a comparable result, with a 
DCR of 69% at 6 weeks  [9] . There are a number of pub-
lished single cases and case series reports of recurrent or 
advanced SCCS treated successfully with cetuximab, con-
sistent with our data  [10–14, 18, 19] . Together, they show 
an overall complete response of 18.5% (17% at 4–8 weeks 
in our case series) and partial response of 29.6% (50% at 
4–8 weeks in our case series)  [15] . These observations 
should encourage a prospective randomized trial of ce-
tuximab therapy in advanced or recurrent SCCS.
 Compared to cisplatin-containing chemotherapy, ce-
tuximab is generally well tolerated, with the exception of a 
notably high incidence of infectious events (total of 36%), 
which were observed mainly in older patients (83% of all 
infections in patients >70 years)  [9] . In our study we also 
observed a major infectious complication in an 85-year-
old patient leading to sepsis and death after three doses of 
cetuximab. Infectious complications in patients receiving 
cetuximab in the context of metastatic head and neck can-
cer showed no overall increase in infections. However,
older head and neck cancer patients >70 years of age us-
ing cetuximab showed up to 33% more infections during
1 year under treatment  [20] . This is a severe and important 
observation. We suggest that particular attention should 
be given to elderly patients receiving cetuximab.
 The most commonly experienced side effect was ac-
ne-like skin rash, occurring in five of the six patients 
(83%). Skin rash is an early and well-known side effect 
of cetuximab treatment and has been reported in 67–
77% of cetuximab-treated patients in prior studies in the 
same treatment setting  [10–14, 18, 19] . In the phase II 
study of 36 treatment-naïve patients with unresectable 
SCCS, patients who developed acne-like skin rash of any 
grade at treatment week 6 tended to have improved 
mean overall survival compared with patients without 
rash (8.9 vs. 4 months, respectively; p = 0.054)  [9] . This 
emphasizes the potential for acne-like rash to predict 
better tumor response to cetuximab in patients with 
SCCS, as demonstrated in studies of patients with 
colorectal and squamous cell cancer of the head and 
neck  [21, 22] . In our patient population we observed 
that all patients who achieved disease control at 4–8 
weeks showed acne-like rash, which might be interpret-
ed in this context.
 Though several Swiss centers contributed to our anal-
ysis, the main limitations of this study are the small num-
ber of cases and the retrospective study design. This case 
series reports an increased use of EGFR inhibitors in met-
astatic SCCS in Switzerland. The efficacy observed in our 
series is consistent with published data and encourages 
the use of EGFR inhibitors in our country. This is consis-
tent with the available literature.
 Conclusions 
 Cetuximab treatment in pretreated patients with met-
astatic SCCS achieved an overall DCR of 67% at 4–8 
weeks of treatment. One of the six included patients 
achieved complete response. These data support further 
investigation of cetuximab in metastatic SCCS and war-
rant a randomized phase III trial comparing cetuximab 
with standard chemotherapy in this setting.
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